Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Treasury Shares for 8 consecutive years, with $1.5 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 26.88% year-over-year to $1.5 million; the TTM value through Mar 2026 reached $1.5 million, up 26.88%, while the annual FY2025 figure was $1.3 million, 79.45% up from the prior year.
  • Treasury Shares hit $1.5 million in Q1 2026 for Kymera Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.5 million in Q1 2026 and bottomed at $121504.0 in Q1 2022.
  • Average Treasury Shares over 5 years is $746263.2, with a median of $636585.0 recorded in 2024.
  • Year-over-year, Treasury Shares skyrocketed 646.7% in 2022 and then increased 26.38% in 2024.
  • Kymera Therapeutics' Treasury Shares stood at $281843.0 in 2022, then soared by 110.45% to $593140.0 in 2023, then increased by 26.38% to $749604.0 in 2024, then surged by 79.45% to $1.3 million in 2025, then grew by 14.13% to $1.5 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $1.5 million, $1.3 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.